Evidence map›Paper›PMID 41807927›Full record

ArticleOncoimmunology2026

Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma.

Jesse R Brown, Bernadette Pedersen, Georgina V Long, Nigel G Maher, Su Yin Lim, Helen Rizos, Elena Shklovskaya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jesse R BrownMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.
Bernadette PedersenMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.ORCID 0000-0002-9278-5663
Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID 0000-0001-8894-3545
Nigel G MaherMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID 0000-0002-8140-2719
Su Yin LimMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.ORCID 0000-0001-9576-5441
Helen RizosMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.ORCID 0000-0002-2094-9198
Elena ShklovskayaMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.ORCID 0000-0002-6155-1020

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced melanoma, yet their efficacy is limited by high-grade immune-related adverse events that often require treatment with systemic corticosteroids. Although corticosteroids are widely used, their impact on anti-tumor immunity remains poorly defined. Using an ICI-responsive murine melanoma model, we show that tapered systemic prednisolone administered after three cycles of combined anti-CTLA4 and anti-PD1 therapy compromises ICI-mediated tumor control, leading to delayed progression in one-third of initially responding animals. Mechanistically, prednisolone selectively suppressed CD8

Indexed as

CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsMelanomaMelanoma, ExperimentalPrednisoloneT-Lymphocytes, RegulatoryAnimalsCell Line, TumorCTLA-4 AntigenCytokinesFemaleHumansLymphocyte ActivationMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorCTLA-4 AntigenCytokinesImmune Checkpoint InhibitorsPrednisoloneProgrammed Cell Death 1 ReceptorimmunosuppressionMelanomamouse modelmultiparameter flow cytometrysystemic steroidsT-cell response

Identifiers

PMID41807927
PMCPMC12987513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.